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Abstract
SPARC-like protein 1 (SPARCL1), a member of the
SPARC family, is downregulated in various tumors. In
the present study, the expression and localization of
SPARCL1wereanalyzed inawide rangeof nontumorous
and neoplastic pancreatic tissues by quantitative re-
verse transcription–polymerase chain reaction, laser
capture microdissection, microarray analysis, and
immunohistochemistry. For functional analysis, pro-
liferation and invasion assays were used in cultured
pancreatic cancer cells. Pancreatic ductal adeno-
carcinoma (PDAC) and other pancreatic neoplasms ex-
hibited increased SPARCL1 mRNA levels compared to
those of the normal pancreas. SPARCL1 mRNA levels
were low to absent in microdissected and cultured
pancreatic cancer cells, and promoter demethylation
increased SPARCL1 levels only slightly in three of eight
cell lines. SPARCL1 was observed in small capillaries
in areas of inflammation/tumor growth and in some
islet cells. In PDAC, 15.4% of vessels were SPARCL1-
positive. In contrast, the percentage of SPARCL1-
positive vessels was higher in chronic pancreatitis
and benign and borderline pancreatic tumors. Recombi-
nant SPARCL1 inhibited pancreatic cancer cell inva-
sion and exerted moderate growth-inhibitory effects. In
conclusion, SPARCL1 expression in pancreatic tissues
is highly correlated with level of vascularity. Its anti-
invasive effects and reduced expression in metastasis
indicate tumor-suppressor function.
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Introduction
The SPARC family of proteins comprises 10 members, two
of which—Secreted Protein Acidic and Rich in Cysteine
(SPARC; also known as osteonectin and BM40) and
SPARC-like protein 1 (SPARCL1; also known as SC1, high
endothelial venule protein, or hevin)—have been implicated
in the progression of a variety of tumors [1–5]. Members of
the SPARC family of proteins modulate cellular functions
through interactions with extracellular matrix (ECM) proteins
and growth factors [6]. SPARC is implicated in the modulation of
cell shape, inhibition of cell cycle, and synthesis/assembly of
ECM, for example, by regulating decorin expression and col-
lagen fibril assembly [7–10]. SPARC-deficient mice suffer from
aberrations in the structure and composition of the ECM that
lead to cataracts, severe osteopenia, accelerated closure of
dermal wounds [11], and accumulation of adipose tissues [7].
SPARC is overexpressed in many tumors of the digestive
tract, such as the colon [12], esophagus [13], and liver [14]; as
well as in tumors of the breast [15], prostate [16], and bladder
[17]; and in melanomas [18], astrocytomas [19], and menin-
giomas [20]. Together with the promotion of invasion and tumor
formation, altered SPARC expression correlates with disease
progression and/or poor prognosis. In pancreatic ductal adeno-
carcinoma (PDAC), SPARC is markedly upregulated and
produced by both cancer cells and surrounding fibroblasts.
Interestingly, recombinant (r) SPARC reduces pancreatic can-
cer cell proliferation and promotes its invasiveness in vitro [21].
SPARCL1 was first isolated from high endothelial cells of
tonsillar venules; it is expressed in a wide range of tissues,
such as tissues of the lymph node, brain, heart, lung, skeletal
muscle, ovary, small intestine, and colon. SPARCL1 levels are
low in the placenta, pancreas, testis, spleen, and thymus,
whereas kidney, liver, and peripheral blood leukocytes are
devoid of SPARCL1 [2].
SPARCL1 is downregulated in transformed prostate epithe-
lial cell lines and metastatic prostate adenocarcinoma [22],
non–small cell lung cancer [23], brain and parathyroid tumors,
and is below detection levels in primary bladder, prostate, and
ovarian tumors [24]. However, SPARCL1 has been identified
as a marker of tumor-associated endothelium [25], but its func-
tion in human tumors is not completely understood. SPARCL1
has antiadhesive properties [2,4], and loss of SPARCL1 ex-
pression, possibly due to deletions/mutations or promoter
hypermethylation [26], is associated with increased proliferative
activity and cell cycle progression [24].
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In the present study, the expression and localization of
SPARCL1 were analyzed in a wide range of nontumorous
and neoplastic pancreatic tissues. In addition, possible reg-
ulators of SPARCL1, as well its effects on tumor growth and
invasion, were investigated.
Materials and Methods
Tissue Samples
Pancreatic tissue specimens were obtained from patients
with a median age of 71 years (range, 43–82 years) in whom
resections for chronic pancreatitis (CP) or pancreatic tumors
were performed. Normal pancreatic (NP) tissue samples
were obtained from previously healthy individuals through
an organ donor program. All samples were confirmed histo-
logically. Freshly removed tissues (within 5 minutes of surgi-
cal excision) were fixed in paraformaldehyde solution for 12
to 24 hours and were subsequently embedded in paraffin
for histologic analysis. Alternatively, tissue samples were em-
bedded in Tissue-Tek OCT compound (Sakura Finetek, Tor-
rance, CA) by freezing blocks in an acetone bath within liquid
nitrogen and were stored at 80jC until use. Tissue arrays
were constructed using a manual tissue arrayer (Beecher
Instruments, Sun Prairie, WI). They contained 34 samples of
primary PDAC and 8 samples of metastatic PDAC, as well as
9 samples of CP, 10 samples of noninflammed and non-
tumorous pancreatic tissues (each sample in triplicate sec-
tions to assure a reliable immunohistochemical expression
profile [27]), and PanIN lesions of different grades (32 low-
grade PanIN lesions and 12 high-grade PanIN lesions). In
addition, a portion of the tissue samples was kept in RNA-
later (Ambion Ltd., Huntingdon, Cambridgeshire, UK) or
snap-frozen in liquid nitrogen immediately on surgical re-
moval and was maintained at 80jC until use. The Human
Subjects Committee of the University of Heidelberg (Heidel-
berg, Germany) and the University of Bern (Bern, Switzer-
land) approved all studies, and written informed consent was
obtained from all patients.
Cell Culture
Pancreatic cancer cell lines were grown routinely in RPMI
medium (Aspc-1, BxPc-3, Capan-1, Colo-357, SU8686, and
T3M4) or DMEM (MiaPaCa-2 and Panc-1 cells), supple-
mented with 10% fetal bovine serum (FBS) and 100 U/ml
penicillin (complete medium), and incubated in a 5% CO2
humidified atmosphere. For induction experiments, 500 pM
transforming growth factor (TGF) b1, 100 ng/ml bone mor-
phogenetic protein (BMP) 2, 10 ng/ml fibroblast growth fac-
tor (FGF) 2, 500 ng/ml sonic hedgehog (Shh), 500 ng/ml
Indian hedgehog (Ihh; R&D Systems GmbH, Wiesbaden-
Nordenstadt, Germany), or 100 ng/ml tumor necrosis factor
(TNF) a (Promega GmbH, Mannheim, Germany) was used.
Real-Time Quantitative Reverse Transcription–Polymerase
Chain Reaction (qRT-PCR)
RT-PCR was performed using the LightCycler FastStart
DNA SYBR Green kit, as previously described [28]. The
number of specific transcripts was normalized to house-
keeping genes (cyclophilin B and HPRT) and presented as
adjusted transcripts per microliter of cDNA.
5-Aza-2 V-Deoxycytidine (5aza-dC) Treatment
Pancreatic cancer cells were plated at a density of 1.5 
106 cells per 10-cm tissue culture plate in complete medium
and allowed to attach over a 24-hour period. 5aza-dC (Sigma-
Aldrich Chemie GmbH, Schnelldorf, Germany) was added
to a final concentration of 1 mM, and cells were cultured for
6 days. The medium was changed every other day. At the
end of treatment, mRNA was extracted as described [29].
Cell Proliferation Assays
To assess pancreatic cancer cell proliferation, 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
assay was used as described previously [29].
Flow Cytometric Analysis
T3M4 and Panc-1 pancreatic cancer cells were plated in
six-well plates (100,000 cells/well) andwere incubated for indi-
cated times with 8 or 125 ng/ml rSPARCL1. Cells were next
harvested, washedwith phosphate-buffered saline (PBS), and
subsequently resuspended in 0.5 ml of hypotonic propidium
iodide (PI) buffer (50 mg/ml PI, 0.1% Triton X-100, and 0.1%
Na-citrate) or 2% PBS and stored overnight at 4jC. Measure-
ments of DNA content or the dose toxicity of rSPARCL1 in
each sample were performed with BD-LSR flow cytometer
(Becton Dickinson and Co., Erembodegem-Aalst, Belgium).
In Vitro Invasion Assays
Briefly, BioCoat Matrigel (BD Biosciences, San Jose, CA)
invasion chambers were rehydrated according to the manu-
facturer’s instructions. Five hundred microliters of RPMI cell
culture medium supplemented with 5% FBS and rSPARCL1
protein at the indicated concentration was added to the
bottom of 24-well plates. Cells were seeded at a density
of 5  104 cells/well into upper inserts. After 24 hours at
37jC, noninvading cells were removed from the upper sur-
face of the separating membrane by gentle scrubbing with
a cotton swab. Invading cells were fixed in 100% methanol
and stained with 0.05% crystal violet in 20% ethanol. Mem-
branes were mounted on glass slides and counted manually
under a light microscope. The invasion index was calcu-
lated as the percentage of invaded cells in the treatment
group compared to the percentage of invaded cells in the
control group. All assays were performed in triplicate.
Laser Capture Microdissection (LCM)
and Microarray Analysis
For this analysis, ductal cells were microdissected from
NP (n = 3), CP (n = 5), and PDAC samples (n = 6). Tissue
sections (6–8 mm thick) were prepared with a Reichard-Jung
1800 cryostat (Leica Microsystems GmbH, Wetzlar, Ger-
many). LCM and RNA extraction were carried out as de-
scribed previously [30]. In addition, RNA was extracted
from 13 normal (nonmicrodissected) pancreatic tissues,
10 CP samples, 10 PDAC samples, and 10 samples of liver
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metastasis of pancreatic cancer. The HG-U95Av2 array from
Affymetrix (Santa Clara, CA) was used for this analysis.
Poly(A)+ RNA isolation, cDNA synthesis, cRNA in vitro tran-
scription, and purification and fragmentation of obtained
products were carried out as reported previously [30]. The
hybridization of fragmented in vitro transcription products
into oligonucleotide arrays was performed as recommended
by the manufacturer.
Immunohistochemistry
Paraffin-embedded tissue sections 2–3 mm thick were
deparaffinized in xylene and rehydrated in progressively de-
creasing concentrations of ethanol. Thereafter, the slides
were placed in washing buffer (10 mMTris–HCl, 0.85%NaCl,
and 0.1% bovine serum albumin, pH 7.4) and subjected to
immunostaining. Antigen retrieval was performed by boiling
consecutive tissue sections in 10 mM citrate buffer for 10 min-
utes in a microwave oven. The sections were incubated with
a goat polyclonal anti-SPARCL1 IgG (R&D Systems GmbH)
or monoclonal mouse anti-human CD34 class IgG1 (DAKO
Corporation, Carpinteria, CA), as well as with normal goat IgG
and normal mouse IgG1 (DAKO Corporation) as negative
controls, respectively. The slides were rinsed with washing
buffer and incubated with anti-goat HRPO-conjugated IgG
(Santa Cruz Biotechnology, Inc., Santa Cruz, CA) or anti-
mouse HRPO-conjugated IgG (Amersham International,
Buckinghamshire, UK) for 1 hour at room temperature. Tis-
sue sections were washed, after which DAB–chromogen
substratemixture (DAKOCorporation)was applied. The slides
were analyzed with the Axioplan 2 imaging microscope (Carl
Zeiss, Go¨ttingen, Germany). Microvessel counting was per-
formed as previously described [31].
Immunoblotting
Cells were treated with 8 and 125 ng/ml rSPARCL1 for
48 hours, washed twice with ice-cold PBS, and lysed with
lysis buffer (50 mM Tris–HCl, 100 mM NaCl, 2 mM EDTA,
and 1% sodium dodecyl sulfate) containing one tablet of
complete mini EDTA-free protease inhibitor cocktail (in
10-ml buffer; Roche Applied Science, Mannheim, Germany).
Cell lysates (20 mg/lane) were separated on sodium dodecyl
sulfate–polyacrylamide gels and electroblotted onto nitro-
cellulose membranes. The membranes were incubated in
blocking solution (5% nonfat dry milk in 20 mM Tris–HCl,
150 mM NaCl, and 0.1% Tween-20), followed by incubation
with mouse monoclonal anti–cyclin D1, rabbit polyclonal
anti–cyclin E, or goat polyclonal anti-p21 (Santa Cruz Bio-
technology, Inc.) overnight at 4jC. The membranes were
washed in blocking solution and incubated with HRP-
conjugated secondary antibodies for 1 hour at room temper-
ature. Antibody detection was performed by an enhanced
chemiluminescence reaction (Amersham International).
Statistical Analysis
Results are expressed as mean ± standard error of the
mean (SEM), unless indicated otherwise. For statistical anal-
ysis, Student’s t test or Mann-Whitney test was used, and
significance was defined as P < .05. Spearman’s r test was
used for correlation analysis, and graphs were generated
using GraphPad prism software (GraphPad Software, San
Diego, CA).
Results
SPARCL1 Expression in Pancreatic Tissues
SPARCL1 mRNA expression levels were analyzed in NP
tissues and compared to those of CP, PDAC, and diverse
pancreatic tumors, using qRT-PCR. As shown in Figure 1,
CP, PDAC, serous cystadenoma (SCA), mucinous cysta-
denoma (MCA), acinar cell carcinoma (ACC), and malignant
neuroendocrine tumor (NET) exhibited higher median
SPARCL1 mRNA levels compared to NP. In contrast, intra-
ductal papillary mucinous neoplasm (IPMN) and benign
NETs exhibited median SPARCL1 mRNA levels lower than
those of NP. The highest median RNA levels (11,248 copies/
ml cDNA) were observed in pancreatic SCA, and the lowest
median RNA levels (651 copies/ml cDNA) were observed in
benign neuroendocrine pancreatic tumor tissues. Interest-
ingly, there was a tendency of higher median SPARCL1
Figure 1. SPARCL1 mRNA expression in the pancreas. RNA was extracted from normal (NP), CP, and PDAC without (N0) or with (N1) lymph node metastasis,
ACC, SCA, benign (B) and malignant (M) IPMN, MCA, benign (B) and malignant (M) NETs, and ampullary carcinoma, as described in the Materials and Methods
section. RNA input was normalized to the average expression of the two housekeeping genes HPRT and cyclophilin B, and is presented as copy number per
microliter of cDNA. Horizontal lines represent the median value. *P < .05, **P < .01, compared to NP.
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mRNA levels in N0 PDAC compared to N1 PDAC cases, and
in malignant compared to benign NETs, but this tendency did
not reach statistical significance. In contrast, there was
no difference in SPARCL1 mRNA levels between benign
and malignant IPMN cases (Figure 1).
Next, SPARCL1 was localized by immunohistochemistry
to identify the source of SPARCL1 in different pancreatic
tissues. Immunohistochemistry revealed that SPARCL1 was
localized in some of the islet cells and in endothelial and
smooth muscle cells of small-sized and medium-sized blood
vessels (Figure 2, A and B), including small capillaries in
areas of inflammation/tumor growth. Interestingly, benign
and inflammatory pancreatic tissues, such as CP (Figure 2C),
SCA (Figure 3C), IPMN, and MCA, exhibited stronger
SPARCL1 staining in vascular structures compared to PDAC.
In contrast, SPARCL1 was below the level of detection in
other structures of pancreatic tissues, especially in cancer
cells in PDAC, tubular complexes, and stromal fibrous tis-
sue elements in both CP (Figure 2C) and PDAC tissues
(Figure 3B). Interestingly, all PanIN-3 lesions (n = 5) exhibited
a specific localization pattern in small capillaries under the
basement membrane, whereas all PanIN-1A (n = 16), 14 of
16 PanIN-1B, and 5 of 7 PanIN-2 lesions did not show this
expression pattern (Figure 2E and F; Figure 3A). Comparable
results were obtained with two additional antibodies: poly-
clonal goat anti-rat SC-1 (Santa Cruz Biotechnology, Inc.)
and rat monoclonal anti-mouse SC-1 [32].
To confirm the specificity of SPARCL1 vascular staining
and to quantify SPARCL1 expression in different pancreatic
tissues, we stained consecutive pancreatic tissue sections
with the endothelial marker CD34 [33]. Tissueswere obtained
from samples of CP, PDAC, and three types of benign cystic
tumors (IPMN, SCA, and MCA). This analysis revealed that
SPARCL1 staining was specific for vascular structures in
pancreatic tissues (Figure 2D; Figure 3,D andF ). Systematic
counting of vessels revealed that: 1) the extent of vascular-
ization according to the expression of CD34 was similar in
different samples, and 2) SPARCL1 was expressed in 15.4 ±
1.6% (PDAC), 32.4 ± 1.4% (CP), 40.4 ± 6.3% (benign IPMN),
66 ± 1.4% (SCA), and 29.9 ± 1.2% (MCA) of CD34-positive
microvessels (Figure 4). Higher levels of the vascular ex-
pression of SPARCL1 were therefore identified in chronic
inflammatory condition (CP) and benign pancreatic cystic
tumors (IPMN, SCA, and MCA) compared to invasive pan-
creatic cancer (PDAC), despite a similar overall density of
CD34-positive vessels.
To confirm absent/low SPARCL1 levels in pancreatic
cancer cells, we asked whether SPARCL1 mRNA was
expressed in cancer cells themselves by the use of LCM
and microarray analysis of microdissected ductal cells. The
mean SPARCL1 mRNA levels in NP (bulk) tissues (n = 13)
were set to 100. In comparison to the expression in normal
tissues, the mean SPARCL1 mRNA levels were 152 in NP
ducts (n = 3), 120 in CP ductal cells (n = 5), and 67 in micro-
dissected cancer cells (n = 6) (Figure 5A). Thus, SPARCL1
expression is reduced in pancreatic cancer cells compared
to NP ductal cells. In addition, microarray analysis of CP
and PDAC bulk tissues, as well as of pancreatic cancer
metastasis to the liver, demonstrated an increase in mean
SPARCL1 mRNA levels in CP (144) and PDAC (186)
Figure 2. Immunohistochemical detection of SPARCL1 and CD34 in benign pancreatic tissues. Immunostaining of paraffin-embedded tissue sections was
performed using the indirect peroxidase technique, as described in the Materials and Methods section. In the normal pancreas, SPARCL1 was detected in some of
the islet cells (A; arrowhead), in the muscular layer (A; arrows), and in the endothelium of preexisting vessels (B; arrows). In addition, in CP, specific staining of
microvessels in areas of tissue remodeling was seen (C; arrows) (microvessels: asterisk, area of tissue remodeling; V, preexisting vein). No staining was detected
in low-grade PanIN lesions (E and F). CD34 staining (D) was used to confirm the specificity of SPARCL1 vascular staining (Figure 4).
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compared to NP tissues (set to 100), which is in agreement
with qRT-PCR data and further confirms that SPARCL1 is
differentially expressed in PDAC. Interestingly, however, the
mean SPARCL1 mRNA level was reduced (54) in liver
metastases of pancreatic cancer (Figure 5B). To further
analyze this aspect, immunohistochemistry was carried out
in samples of pancreatic cancer metastasis to the liver
(n = 10), lymph nodes (n = 4), and peritoneum (n = 9). This
analysis revealed absent SPARCL1 staining in metastatic
cancer cells and occasional SPARCL1 expression in asso-
ciated tumor capillaries (Figure 6).
SPARCL1 Expression and Transcriptional Regulation
in Pancreatic Cancer Cells
qRT-PCR analysis of eight cultured pancreatic cancer cell
lines showed essentially no SPARCL1 mRNA in four of eight
pancreatic cancer cells and low mRNA levels in four of eight
pancreatic cancer cells, with a range of 2.8 to 40.5 copies/ml
cDNA (Figure 7A). Immunocytochemistry was performed on
eight pancreatic cancer cells, in which SPARCL1 was below
the level of detection in all tested cells (data not shown). To
exclude SPARCL1 promoter hypermethylation as a cause
of low transcript levels, we treated all pancreatic cancer cells
with a 5aza-dC demethylation reagent, followed by qRT-
PCR analysis. This analysis revealed a 3.2-fold, 3.8-fold, and
1.1-fold increase in SPARCL1 mRNA expression in Colo-357,
SU8686, and T3M4 cells, respectively (Figure 7A), and no
effect in the other five cell lines. Thus, promoter hyper-
methylation is not the dominant mechanism of the observed
low to absent SPARCL1 expression in pancreatic cancer cells.
The regulation of SPARCL1 mRNA expression by a num-
ber of growth factors and cytokines that are known to influence
the behavior of pancreatic cancer cells [34,35] was examined.
Analysis revealed that SPARCL1 mRNA expression was not
affected in any of the pancreatic cancer cells tested, with
the exception of T3M4 cells. In this cell line, SPARCL1 mRNA
was induced by Ihh (500 ng/ml), Shh (500 ng/ml), and FGF-2
(10 ng/ml), with effects (percentage of control) of +91.7 ±
2.7%, +59.3 ± 8.1%, and +46 ± 4.9%, respectively. Treatment
of T3M4 cells with TNF-a (100 ng/ml) reduced SPARCL1
Figure 3. Immunohistochemical detection of SPARCL1 and CD34 in neoplastic pancreatic tissues. Immunostaining of paraffin-embedded tissue sections was
performed using the indirect peroxidase technique, as described in the Materials and Methods section. High-grade PanIN showed SPARCL1-positive microvessels
under the basement membrane (A). Ductal adenocarcinoma cells were always negative (B and E; asterisk); weak to moderate staining was detected in some of the
small vessels of the tumor stroma (B and E). Benign pancreatic tumors, such as SCA, displayed moderate staining in numerous microvessels of the tumor stroma
(C). CD34 staining (D and F) was used to confirm the specificity of SPARCL1 vascular staining (Figure 4).
Figure 4. Semiquantification of SPARCL1/CD34 vascular expression in
pancreatic tissues by immunohistochemistry. SPARCL1 and CD34 immuno-
histochemistry was performed in consecutive pancreatic tissue sections
from PDAC, CP, IPMN, SCA, and MCA, as described in the Materials and
Methods section. SPARCL1 vascular expression was evaluated in these tis-
sues (gray columns) compared to CD34 expression (black column). Values
represent the mean ± SEM of the number of vessels counted in three different
areas (20 per high-power field).
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Figure 5. (A) SPARCL1 mRNA expression in microdissected pancreatic ductal cells. Microarray analysis for the mRNA levels of SPARCL1 from NP tissues (n = 13),
NP ducts (n = 3), ducts from CP tissues (n = 5), and cancer cells (n = 6). Values represent arbitrary units normalized to housekeeping genes [30] and NP tissues
(mean set to 100). (B) SPARCL1 mRNA expression in bulk pancreatic tissues. Microarray analysis for the mRNA levels of SPARCL1 from NP tissues (n = 13), CP
(n = 10), PDAC tissues (n = 10), and liver metastases of pancreatic cancer (n = 10). Values represent arbitrary units normalized to housekeeping genes [30] and
NP tissues (mean set to 100). Horizontal bars represent mean values.
Figure 6. Immunohistochemical detection of SPARCL1 and CD34 in metastatic pancreatic cancer. Immunostaining of paraffin-embedded tissue sections was
performed using the indirect peroxidase technique, as described in the Materials and Methods section. Liver metastasis (A and B) and lymph node metastasis
(C and D). Note the absence of SPARCL1 staining in metastatic cancer cells (A and C; arrows). Occasionally, blood vessels were SPARCL1-positive (C;
arrowheads). CD34 staining was used to identify blood vessels (B and D; arrowheads).
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mRNA significantly by 40.3 ± 1.6%. TGF-b1 (500 pM) and
BMP-2 (100 ng/ml) did not significantly influence SPARCL1
mRNA levels in T3M4 cells (Figure 7B).
SPARCL1 Reduces the Invasion of Pancreatic Cancer Cells
We next asked whether the treatment of two pancreatic
cancer cell lines (T3M4 and Panc-1) with rSPARCL1 af-
fected proliferation or invasiveness. MTT assays revealed a
concentration-dependent inhibition of growth with maximum
effects of 35.5 ± 3.9% in T3M4 and 38.2 ± 6.5% in Panc-1
cells at 125 ng/ml (1.28 nM) rSPARCL1 (Figure 8, A and B).
PI staining of T3M4 and Panc-1 cells excluded potential
toxic effects of rSPARCL1 (data not shown). Fluorescence-
activated cell sorter analysis was performed to investigate a
mechanism by which the proliferation of T3M4 and Panc-1
cells was reduced. Although T3M4 cells did not show detect-
able changes in cell cycle in response to rSPARCL1 after
48 hours, Panc-1 cells exhibited a minor (+2% and +5.2%)
accumulation in G0/G1 phase at a concentration of 8 and
125 ng/ml rSPARCL1 after 48 hours, respectively (data not
shown). These effects were not accompanied by changes
in the expression of cell cycle–regulatory proteins cyclins
D1 and E, or the tumor-suppressor protein p21 (data not
shown). There was no apoptotic cell death induced by
rSPARCL1 in both Panc-1 and T3M4 cells at indicated con-
centrations and duration of treatment.
Matrigel invasion assays were performed on T3M4 and
Panc-1 cells in the presence or in the absence of indicated
concentrations of rSPARCL1 (Figure 9). rSPARCL1 reduced
invasion by 68.5 ± 2.8% in T3M4 cells, and by 34.2 ± 1.8% in
Panc-1 cells, at a concentration of 8 ng/ml. The inhibitory
effects were less pronounced at 125 ng /ml rSPARCL1,
at which T3M4 exhibited reduction in invasion by 44.4 ±
7.4% and Panc-1 exhibited reduction in invasion by 26.8 ±
1.2% (Figure 9).
Discussion
The expression of SPARCL1, which is an abundant matricel-
lular protein that modulates high endothelial cell adhesion to
Figure 7. SPARCL1 mRNA expression in pancreatic cancer cell lines. (A) Real-time qRT-PCR analysis of SPARCL1 mRNA levels in pancreatic cancer cell lines.
mRNA was extracted from eight pancreatic cancer cell lines without (black column) or with (gray column) treatment with 5aza-dC demethylation reagent, as
described in the Materials and Methods section. (B) Transcriptional regulation of SPARCL1 by cytokines and growth factors. T3M4 pancreatic cancer cells were
treated with TGF-1, BMP-2, FGF-2, TNF-a, Shh, and Ihh (gray columns), or were not treated (black column). RNA was extracted, and qRT-PCR was performed
as described in the Materials and Methods section. Values represent the mean ± SEM of three independent experiments. RNA input was normalized to the average
expression of the two housekeeping genes HPRT and cyclophilin B, and is presented as copy number per microliter of cDNA.
Figure 8. The effects of rSPARCL1 on the proliferation of (A) T3M4 and (B) Panc-1 pancreatic cancer cells, as determined by the MTT assay. Pancreatic cancer
cells were incubated with rSPARCL1 at the indicated concentrations (in ng/ml) for 48 hours before analysis. Data are expressed as the percentage of change
compared to controls, and are plotted as the mean ± SEM of three independent experiments. *P < .05, **P < .01, compared to controls.
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the basement membrane and may facilitate lymphocytic
migration/extravasation [2,36], is deregulated in various
tumors. The results of the present study show that SPARCL1
mRNA expression in NP tissues was mainly accounted for
in islets together with preexistent vascular structures. The
median SPARCL1 mRNA levels were increased in PDAC
tissues compared to NP tissues, a change due specifically to
the expression of SPARCL1 in small vessels formed as a
result of neoangiogenesis in PDAC tissues. This finding is in
accordance with previous observations showing SPARCL1
as a marker of angioendothelial cells in pancreatic cancer
[37]. Furthermore, benign and inflammatory pancreatic
lesions such as CP, SCA, and MCA tissues (the last two
characterized by CP-like changes in the surrounding stroma,
with tissue remodeling and neoangiogenesis) [38,39] ex-
pressed higher levels of SPARCL1 mRNA than were ob-
served in PDAC tissues and liver metastases of PDAC.
These data indicate that SPARCL1 expression in inflamma-
tory and neoplastic pancreatic lesions depends on the extent
of neovascularization, regardless of the type of lesion. The
lower levels of SPARCL1 mRNA in PDAC tissues (primary
and also metastatic) compared to CP and benign cystic
lesions could be due to its downregulation, as has been de-
scribed in other human cancers. SPARCL1 contributes to the
induction or maintenance of the features of the high endo-
thelial venule endothelium that facilitates lymphocyte mi-
gration [2] and provides immune surveillance [40]. Thus,
increased expression of SPARCL1 in reactive vascular struc-
tures in benign and inflammatory lesions might contribute
to the support of immune response in these lesions [41]. In
contrast, decreased or lost expression of SPARCL1 in re-
active vessels in PDAC might alter the permeability of the
endothelium and the extravasation of immune cells, thus
impairing immune response against cancer cells in PDAC
tissues [2,36]. Additionally, the higher SPARCL1 mRNA
levels in microdissected ductal cells from NP and CP tissues
compared to pancreatic cancer cells, as well as the low-to-
absent SPARCL1 mRNA levels in cultured pancreatic cancer
cell lines and the liver metastases of pancreatic cancer,
provide further support to the hypothesis that SPARCL1 acts
as a tumor suppressor, the expression of which is lost in
PDAC cells.
The mechanisms of SPARCL1 downregulation in PDAC
are not completely understood. Promoter hypermethylation
is one of the factors that mask the expression of genes in
pancreatic cancer [42]. SPARCL1 promoter demethylation
increasedSPARCL1mRNA levels in three of eight pancreatic
cancer cell lines, but these increased levels were still approx-
imately 100-fold lower than those observed in bulk pancre-
atic cancer tissues, an observation suggesting that promoter
hypermethylation is not the key mechanism by which
SPARCL1 expression is repressed in pancreatic cancer cells.
Transcriptional regulation of SPARCL1 by other factors
such as cytokines may be another reason for the reduced
expression of SPARCL1 mRNA in pancreatic cancer cells.
Supporting this theory, SPARCL1 transcription was regulated
by proteins that show frequent derangement in PDAC, such
as FGF-2 [43], TNF-a [44], Shh [45], and Ihh [46,29]. Sur-
prisingly, SPARCL1 mRNA expression levels were de-
creased in response to TNF-a (a factor with antiproliferative
effects on pancreatic cancer cells) [47] and were increased
in response to other factors that have mitogenic effects on
pancreatic cancer cells, such as FGF-2 [43], Shh [45], and
Ihh [29]. Nevertheless, these effects were observed in only
one of eight cell lines and were quite minimal. The maximum
increase in SPARCL1 mRNA was less than two-fold, and
basal levels of SPARCL1 mRNA in T3M4 cells were only
24.6 copies/ml cDNA. Thus, the effects of SPARCL1 on pan-
creatic cancer cells are paracrine rather than autocrine (i.e.,
SPARCL1 produced by endothelia, but not by cancer cells,
affects pancreatic cancer cell invasion). Antiadhesive effects
on pancreatic cancer cells were confirmed using rSPARCL1.
Ideally, this observation could further be substantiated by
knock-down and knock-in experiments. However, SPARCL1
expression levels were too low in cultured pancreatic cancer
cells for further knock-down experiments. However, forced
overexpression of SPARCL1 on the protein level has not
been achieved in cultured cell lines (Weaver et al., un-
published observation). Nonetheless, we believe that the
antiadhesive effects observed with rSPARCL1 in pancreatic
cancer cells represent a true physiologic effect.
Analysis of SPARCL1 in PanIN lesions allowed two im-
portant observations. First, a significant level of neoangio-
genesis was associated mainly with high-grade lesions,
Figure 9. The effects of rSPARCL1 on the invasion of T3M4 and Panc-1 pancreatic cancer cells. (A) T3M4 and (B) Panc-1 pancreatic cancer cells were incubated
with 0, 8, or 125 ng/ml rSPARCL1 for 24 hours. Invasion was analyzed by Matrigel invasion assays, as described in the Materials and Methods section. Data are
presented as the percentage of invasion compared to control cells (100%) and are plotted as the mean ± SEM of three independent experiments. *P < .05, **P <
.01, compared to controls.
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indicating a prominent stromal remodeling in the immediate
preinvasive stage. Second, the downregulation of SPARCL1
takes place in the late stage of pancreatic cancer progres-
sion. That downregulation is a late event was also supported
by the finding that N1 PDAC cases showed a tendency for
lower SPARCL1 mRNA levels compared to N0 PDAC cases,
as has been shown for metastatic prostate carcinoma [22].
In conclusion, SPARCL1 expression in pancreatic tissues
corresponds to vascular content. SPARCL1 is downregulated
in PDAC cells, and supplementation of these cells with
rSPARCL1 has anti-invasive effects, supporting a tumor-
suppressor function for this matricellular protein.
References
[1] Findlay DM, Fisher LW, McQuillan CI, Termine JD, and Young MF
(1988). Isolation of the osteonectin gene: evidence that a variable re-
gion of the osteonectin molecule is encoded within one exon. Bio-
chemistry 27, 1483–1489.
[2] Girard JP and Springer TA (1995). Cloning from purified high endothe-
lial venule cells of hevin, a close relative of the antiadhesive extra-
cellular matrix protein SPARC. Immunity 2, 113–123.
[3] Johnston IG, Paladino T, Gurd JW, and Brown IR (1990). Molecular
cloning of SC1: a putative brain extracellular matrix glycoprotein show-
ing partial similarity to osteonectin/BM40/SPARC. Neuron 4, 165–176.
[4] Sullivan MM and Sage EH (2004). Hevin/SC1, a matricellular glyco-
protein and potential tumor-suppressor of the SPARC/BM-40/Osteo-
nectin family. Int J Biochem Cell Biol 36, 991–996.
[5] Swaroop A, Hogan BL, and Francke U (1988). Molecular analysis of the
cDNA for human SPARC/osteonectin/BM-40: sequence, expression,
and localization of the gene to chromosome 5q31–q33. Genomics 2,
37–47.
[6] Bornstein P and Sage EH (2002). Matricellular proteins: extracellular
modulators of cell function. Curr Opin Cell Biol 14, 608–616.
[7] Bradshaw AD, Graves DC, Motamed K, and Sage EH (2003). SPARC-
null mice exhibit increased adiposity without significant differences in
overall body weight. Proc Natl Acad Sci USA 100, 6045–6050.
[8] Brekken RA, Puolakkainen P, Graves DC, Workman G, Lubkin SR, and
Sage EH (2003). Enhanced growth of tumors in SPARC null mice is
associated with changes in the ECM. J Clin Invest 111, 487–495.
[9] Goldblum SE, Ding X, Funk SE, and Sage EH (1994). SPARC (secreted
protein acidic and rich in cysteine) regulates endothelial cell shape and
barrier function. Proc Natl Acad Sci USA 91, 3448–3452.
[10] Sullivan MM, Barker TH, Funk SE, Karchin A, Seo NS, Hook M,
Sanders J, Starcher B, Wight TN, Puolakkainen P, et al. (2006). Matri-
cellular hevin regulates decorin production and collagen assembly.
J Biol Chem 281, 27621–27632.
[11] Gilmour DT, Lyon GJ, Carlton MB, Sanes JR, Cunningham JM,
Anderson JR, Hogan BL, Evans MJ, and Colledge WH (1998). Mice
deficient for the secreted glycoprotein SPARC/osteonectin/BM40 de-
velop normally but show severe age-onset cataract formation and dis-
ruption of the lens. EMBO J 17, 1860–1870.
[12] Porte H, Chastre E, Prevot S, Nordlinger B, Empereur S, Basset P,
Chambon P, and Gespach C (1995). Neoplastic progression of human
colorectal cancer is associated with overexpression of the stromelysin-3
and BM-40/SPARC genes. Int J Cancer 64, 70–75.
[13] Porte H, Triboulet JP, Kotelevets L, Carrat F, Prevot S, Nordlinger B,
DiGioia Y, Wurtz A, Comoglio P, Gespach C, et al. (1998). Over-
expression of stromelysin-3, BM-40/SPARC, and MET genes in human
esophageal carcinoma: implications for prognosis. Clin Cancer Res 4,
1375–1382.
[14] Le Bail B, Faouzi S, Boussarie L, Guirouilh J, Blanc JF, Carles J,
Bioulac-Sage P, Balabaud C, and Rosenbaum J (1999). Osteonectin/
SPARC is overexpressed in human hepatocellular carcinoma. J Pathol
189, 46–52.
[15] Bellahcene A and Castronovo V (1995). Increased expression of osteo-
nectin and osteopontin, two bone matrix proteins, in human breast
cancer. Am J Pathol 146, 95–100.
[16] Jacob K, Webber M, Benayahu D, and Kleinman HK (1999). Osteo-
nectin promotes prostate cancer cell migration and invasion: a possible
mechanism for metastasis to bone. Cancer Res 59, 4453–4457.
[17] Yamanaka M, Kanda K, Li NC, Fukumori T, Oka N, Kanayama HO, and
Kagawa S (2001). Analysis of the gene expression of SPARC and its
prognostic value for bladder cancer. J Urol 166, 2495–2499.
[18] Ledda F, Bravo AI, Adris S, Bover L, Mordoh J, and Podhajcer OL
(1997). The expression of the secreted protein acidic and rich in cys-
teine (SPARC) is associated with the neoplastic progression of human
melanoma. J Invest Dermatol 108, 210–214.
[19] Rempel SA, Golembieski WA, Ge S, Lemke N, Elisevich K, Mikkelsen T,
and Gutierrez JA (1998). SPARC: a signal of astrocytic neoplastic
transformation and reactive response in human primary and xenograft
gliomas. J Neuropathol Exp Neurol 57, 1112–1121.
[20] Rempel SA, Ge S, and Gutierrez JA (1999). SPARC: a potential diag-
nostic marker of invasive meningiomas. Clin Cancer Res 5, 237–241.
[21] Guweidhi A, Kleeff J, Adwan H, Giese NA, Wente MN, Giese T, Buchler
MW, Berger MR, and Friess H (2005). Osteonectin influences growth
and invasion of pancreatic cancer cells. Ann Surg 242, 224–234.
[22] Nelson PS, Plymate SR, Wang K, True LD, Ware JL, Gan L, Liu AY, and
Hood L (1998). Hevin, an antiadhesive extracellular matrix protein, is
down-regulated in metastatic prostate adenocarcinoma. Cancer Res
58, 232–236.
[23] Bendik I, Schraml P, and Ludwig CU (1998). Characterization of
MAST9/Hevin, a SPARC-like protein, that is down-regulated in non–
small cell lung cancer. Cancer Res 58, 626–629.
[24] Claeskens A, Ongenae N, Neefs JM, Cheyns P, Kaijen P, Cools M, and
Kutoh E (2000). Hevin is down-regulated in many cancers and is a
negative regulator of cell growth and proliferation. Br J Cancer 82,
1123–1130.
[25] St Croix B, Rago C, Velculescu V, Traverso G, Romans KE, Montgomery
E, Lal A, Riggins GJ, Lengauer C, Vogelstein B, et al. (2000). Genes
expressed in human tumor endothelium. Science 289, 1197–1202.
[26] Isler SG, Schenk S, Bendik I, Schraml P, Novotna H, Moch H, Sauter G,
and Ludwig CU (2001). Genomic organization and chromosomal map-
ping of SPARC-like 1, a gene down regulated in cancers. Int J Oncol 18,
521–526.
[27] Shergill IS, Shergill NK, Arya M, and Patel HR (2004). Tissue micro-
arrays: a current medical research tool. Curr Med Res Opin 20,
707–712.
[28] Kayed H, Kleeff J, Keleg S, Buchler MW, and Friess H (2003). Distri-
bution of Indian hedgehog and its receptors patched and smoothened in
human chronic pancreatitis. J Endocrinol 178, 467–478.
[29] Kayed H, Kleeff J, Keleg S, Guo J, Ketterer K, Berberat PO, Giese N,
Esposito I, Giese T, Buchler MW, et al. (2004). Indian hedgehog sig-
naling pathway: expression and regulation in pancreatic cancer. Int J
Cancer 110, 668–676.
[30] Ketterer K, Rao S, Friess H, Weiss J, Buchler MW, and Korc M (2003).
Reverse transcription–PCR analysis of laser-captured cells points to
potential paracrine and autocrine actions of neurotrophins in pancreatic
cancer. Clin Cancer Res 9, 5127–5136.
[31] Esposito I, Menicagli M, Funel N, Bergmann F, Boggi U, Mosca F,
Bevilacqua G, and Campani D (2004). Inflammatory cells contribute
to the generation of an angiogenic phenotype in pancreatic ductal
adenocarcinoma. J Clin Pathol 57, 630–636.
[32] Brekken RA, Sullivan MM, Workman G, Bradshaw AD, Carbon J,
Siadak A, Murri C, Framson PE, and Sage EH (2004). Expression
and characterization of murine hevin (SC1), a member of the SPARC
family of matricellular proteins. J Histochem Cytochem 52, 735–748.
[33] Simmons DL, Satterthwaite AB, Tenen DG, and Seed B (1992). Molec-
ular cloning of a cDNA encoding CD34, a sialomucin of human hema-
topoietic stem cells. J Immunol 148, 267–271.
[34] Kayed H, Kleeff J, Osman T, Keleg S, Buchler MW, and Friess H (2006).
Hedgehog signaling in the normal and diseased pancreas. Pancreas
32, 119–129.
[35] Korc M (1998). Role of growth factors in pancreatic cancer. Surg Oncol
Clin North Am 7, 25–41.
[36] Girard JP and Springer TA (1996). Modulation of endothelial cell adhe-
sion by hevin, an acidic protein associated with high endothelial ve-
nules. J Biol Chem 271, 4511–4517.
[37] Iacobuzio-Donahue CA, Ryu B, Hruban RH, and Kern SE (2002). Ex-
ploring the host desmoplastic response to pancreatic carcinoma: gene
expression of stromal and neoplastic cells at the site of primary inva-
sion. Am J Pathol 160, 91–99.
[38] Kosmahl M, Wagner J, Peters K, Sipos B, and Kloppel G (2004). Se-
rous cystic neoplasms of the pancreas: an immunohistochemical anal-
ysis revealing alpha-inhibin, neuron-specific enolase, MUC6 as new
markers. Am J Surg Pathol 28, 339–346.
[39] Zamboni G, Scarpa A, Bogina G, Iacono C, Bassi C, Talamini G, Sessa
F, Capella C, Solcia E, Rickaert F, et al. (1999). Mucinous cystic tumors
16 SPARCL1 in Pancreatic Tumors Esposito et al.
Neoplasia . Vol. 9, No. 1, 2007
of the pancreas: clinicopathological features, prognosis, and rela-
tionship to other mucinous cystic tumors. Am J Surg Pathol 23,
410–422.
[40] Picker LJ (1992). Mechanisms of lymphocyte homing. Curr Opin Immu-
nol 4, 277–286.
[41] Barker TH, Framson P, Puolakkainen PA, Reed M, Funk SE, and Sage
EH (2005). Matricellular homologs in the foreign body response: hevin
suppresses inflammation, but hevin and SPARC together diminish an-
giogenesis. Am J Pathol 166, 923–933.
[42] Okami J, Simeone DM, and Logsdon CD (2004). Silencing of the hypoxia-
inducible cell death protein BNIP3 in pancreatic cancer. Cancer Res 64,
5338–5346.
[43] Yamanaka Y, Friess H, Buchler M, Beger HG, Uchida E, Onda M,
Kobrin MS, and Korc M (1993). Overexpression of acidic and basic
fibroblast growth factors in human pancreatic cancer correlates with
advanced tumor stage. Cancer Res 53, 5289–5296.
[44] Watanabe N, Tsuji N, Tsuji Y, Sasaki H, Okamoto T, Akiyama S,
Kobayashi D, Sato T, Yamauchi N, and Niitsu Y (1996). Endogenous
tumor necrosis factor inhibits the cytotoxicity of exogenous tumor ne-
crosis factor and adriamycin in pancreatic carcinoma cells. Pancreas
13, 395–400.
[45] Thayer SP, di Magliano MP, Heiser PW, Nielsen CM, Roberts DJ,
Lauwers GY, Qi YP, Gysin S, Fernandez-del Castillo C, Yajnik V, et al.
(2003). Hedgehog is an early and late mediator of pancreatic cancer
tumorigenesis. Nature 425, 851–856.
[46] Berman DM, Karhadkar SS, Maitra A, Montes De Oca R, Gerstenblith
MR, Briggs K, Parker AR, Shimada Y, Eshleman JR, Watkins DN, et al.
(2003). Widespread requirement for Hedgehog ligand stimulation in
growth of digestive tract tumours. Nature 425, 846–851.
[47] Schmiegel WH, Caesar J, Kalthoff H, Greten H, Schreiber HW, and
Thiele HG (1988). Antiproliferative effects exerted by recombinant
human tumor necrosis factor-alpha (TNF-alpha) and interferon-gamma
(IFN-gamma) on human pancreatic tumor cell lines. Pancreas 3,
180–188.
SPARCL1 in Pancreatic Tumors Esposito et al. 17
Neoplasia . Vol. 9, No. 1, 2007
